logo
The world's first genetically modified spider could lead to new ‘supermaterials'

The world's first genetically modified spider could lead to new ‘supermaterials'

Fast Company22-05-2025
Researchers funded by the U.S. Navy have used gene-editing technology to make house spiders produce red fluorescent silk. This might seem like a quirky scientific novelty, but the breakthrough is a critical step toward modifying spider silk properties and creating new 'supermaterials' for industries ranging from textiles to aerospace.
The team at Germany's University of Bayreuth, led by Professor Thomas Scheibel, successfully applied CRISPR-Cas9—a molecular tool that acts as 'genetic scissors' to cut and modify DNA sequences—to spiders for the first time. The study, published in the scientific journal Angewandte Chemi e, demonstrates how this technology introduces modifications that enhance the extraordinary properties of spider silk, turning it into a next-generation supermaterial. In a press release, professor Thomas Scheibel, chair of biomaterials at the University of Bayreuth and senior author of the study, said, 'Considering the wide range of possible applications, it is surprising that there have been no studies to date using CRISPR-Cas9 in spiders.'
His team injected a solution containing CRISPR-Cas9 components into female Parasteatoda tepidariorum, a common house spider species. To facilitate the process, the spiders were anesthetized with carbon dioxide and manually held under a microscope. The solution, which included a gene encoding a red fluorescent protein (called mRFP), was delivered into the eggs within the females' abdomens before mating with males so the resulting baby spiders could carry the gene modification.
What are scientists trying to do?
The experiment set two objectives: first, to disable a gene called sine oculis, responsible for the development of all spider eyes, in order to study its function. And then second, to insert the fluorescent protein gene into the MaSp2gene, which produces the silk thread spiders use to move hunt, hike, and chill out. In modified specimens, disabling sine oculis caused total or partial eye loss, confirming its critical role in visual development. According to the study, without this gene spiders fail to form eye structures, though the cornea develops normally.
But the breakthrough with far-reaching industrial implications is the silk modification. The injected fluorescent protein gene successfully integrated into the MaSp2 gene, causing fibers produced by the modified spiders to glow red under ultraviolet light.
According to Scheibel, they 'have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into spider silk proteins, thereby enabling the functionalisation of these silk fibres.' He says that the ability to apply CRISPR gene-editing to spider silk is very promising for materials science research—for example, it could be used to further increase the already high tensile strength of spider silk.'
This accomplishment was no small feat. Spider genomes are complex, and their embryonic development—marked by unique cell migration stages—complicates genetic editing, according to the researchers. In fact, only 7% of egg sacs that were treated with the CRISPR solution contained modified offspring, a low efficiency rate typical for species with large broods (common house spiders carry about 250 spiders per sac). Additionally, the spiders they used are cannibalistic nature, which required them to be reared in isolation (not all spiders are cannibalistic in nature, but many do eat their males after mating and others eat each other).
The race for 'super silk'
It's a very promising development indeed. Spider silk is one of nature's strongest materials. Certain types of spider silk are significantly lighter and tougher than Kevlar. Silk is also far more elastic, which means it can stretch and return to its original shape without losing its strength. To top all this, spider silk production by spiders (or other animals, more on this later) does not involve the industrial processes, high energy consumption, and pollution associated with the manufacturing of synthetic materials like Kevlar. This is a major area of interest for biomimicry and sustainable materials.
Until now, modifying spider silk's properties required costly, lab-based post-extraction processing, which is difficult to scale. This study shows that altering silk directly within the organism is feasible, paving the way for custom-designed silks with enhanced properties.
While spider silk remains unmatched in natural performance, CRISPR-edited silkworms are emerging as scalable alternatives. Silkworms can be farmed en masse (unlike solitary, cannibalistic spiders), and recent advances show their engineered silk reaches 1.3 GPa tensile strength, comparable to high-tensile steel, which is a steel alloyed with chromium, molybdenum, manganese, nickel, silicon, and vanadium. Companies like Kraig Biocraft Laboratories already use CRISPR to produce spider-silk hybrids in silkworms, targeting industries like textiles and medical sutures.
However, spider silk holds unique advantages over those genetically modified silkworms. Its dragline fibers are inherently stronger and 10 times finer. Using the method developed by Scheibel's team, potential CRISPR-enhanced spiders are likely to gain more superpowers, like getting closer to Kevlar or gaining better electrical conductivity.
Where super silk might be used
In medicine, spider silk's biocompatibility makes it ideal for dissolvable surgical sutures that reduce scarring and artificial tendons mimicking natural elasticity. Researchers are also developing 3D-printed scaffolds infused with silk proteins to regenerate bone or cartilage, leveraging silk's porous structure to support cell growth. For drug delivery, silk microcapsules could release medications at controlled rates, improving treatments for chronic diseases. New applications can integrate silk in sensors for real-time health monitoring in implants or conduct electricity for flexible electronics.
The U.S. Navy's funding of the research makes sense too, given its interest in lightweight body armor. Spider silk can outperform Kevlar, while its elasticity reduces blunt-force trauma. In aerospace, silk composites could replace carbon fiber, cutting aircraft weight by 40% and improving fuel efficiency. NASA already explores silk-based materials for radiation shielding in space habitats, capitalizing on its strength-to-weight ratio.
Companies like AMSilk and Spintex engineer spider silk proteins into biodegradable textiles, reducing reliance on synthetic fabrics derived from fossil fuels. Adidas has prototyped ultralight running shoes with silk midsoles, while Airbus tests silk-based cabin panels to lower aircraft emissions. Spintex claims that its energy-efficient spinning process—1,000 times more efficient than plastic production—could revolutionize sustainable fashion, addressing the industry's 10% global carbon footprint.
Right now, Scheibel's team is already exploring CRISPR edits to add moisture-responsive shrinking or toxin-detecting color changes to silk.
Once they achieve whatever new wundersilks they—or the U.S. Navy—have in mind, they will have to come up with a way to mass-produce them. This evokes images of farms full of millions of genetically modified spiders, which sounds as fun as a rave with 10,000 zombies from The Last of Us. But the spider farms may never happen: As the researchers mention, many spiders are cannibals and the success rate of modification is still very low, so this will be a challenge. That is what makes genetically modified silkworms ideal to make spider-like silks, as they have been farmed for silk production since the neolithic, about 6,000 years ago, when Yangshao culture in China realized that silkworms could be raised to harvest cocoons that then got weaved to create silk fabric.
The solution may be taking the successful spider DNA modifications they develop and using other animals to produce them, like silkworms or goats (yes, spider-goats are a thing). I'll leave you at this point. Good luck in your dreams tonight, my arachnophobic friends.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Optimizing Therapies for HR+ Early-Stage Breast Cancer
Optimizing Therapies for HR+ Early-Stage Breast Cancer

Medscape

time7 minutes ago

  • Medscape

Optimizing Therapies for HR+ Early-Stage Breast Cancer

Hormone receptor-positive (HR+) early-stage breast cancer is one of the most common types of breast cancer, characterized by tumor cells that have receptors for estrogen or progesterone hormones. Although significant progress has been made in screening, treatment, and surgery, the risk of recurrence still remains. To explore therapies for managing HR+ early-stage breast cancer, Medscape spoke with Hope S. Rugo, MD, FASCO, division chief of breast medical oncology and a professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Center, Duarte, California, and professor emeritus at the University of California San Francisco. Read on for her insights. What role does risk stratification play in determining therapy for HR+ early-stage breast cancer? Hope S. Rugo, MD, FASCO This is a critical area. It is a key aspect of determining appropriate treatment and extent of treatment, and we are still learning more about how to appropriately stratify based on clinicopathologic and genomic characteristics. Gene expression tests are used widely to understand prognosis and benefit from chemotherapy, but there are ongoing issues in HR+ disease including disease heterogeneity and how to optimally treat very young women with HR+ disease. We use clinicopathologic data in combination with gene expression tests to stratify risk, but this approach doesn't always provide us with the necessary information for determining the optimal adjuvant or neoadjuvant treatment. The adjuvant CDK4/6 inhibitor trials will be helpful, as they will allow for longer follow-up of patients with high- and intermediate-risk disease. Additionally, newer predictors, such as gene expression signatures that may estimate the benefit from immunotherapy, are also being evaluated. What factors influence your choice between endocrine therapy and chemotherapy for HR+ early-stage breast cancer? Multiple factors have an influence on the choice of therapy, including the extent of disease and tumor biology. We have also learned that the intensity or extent of estrogen positivity plays a role in endocrine sensitivity. In terms of tumor biology, understanding tumor proliferation and chemotherapy sensitivity is critical. We are currently using gene expression tests, but it is clear that these are insufficient, even within the context of age and tumor burden. Additional markers that help to identify up-front or emerging resistance to endocrine therapy are critical. Data from the CDK4/6 inhibitor adjuvant trials has further complicated this question — as now the issue is where optimal outcome can be achieved in less chemotherapy-responsive, higher-risk disease with the addition of abemaciclib or ribociclib. Considering recent research, is extended endocrine therapy actually beneficial? I believe it is, but careful consideration needs to be given to the decision to extend therapy. Disease burden is of course our first consideration, but sensitivity to endocrine therapy, development of resistance, and response to chemotherapy in appropriate cases need to be taken into consideration. Interestingly, several analyses have suggested that patients with low proliferative and genomic risk, but a higher disease burden, might be most likely to benefit from extended duration endocrine therapy due to the long natural history of this disease. We are now exploring the use of switching the type of endocrine therapy in the high-risk adjuvant setting and the use of circulating tumor DNA (ctDNA) to optimize therapy. What role do CDK4/6 inhibitors play in the adjuvant setting for HR+ early-stage disease? Both abemaciclib and ribociclib have reduced the risk of recurrence and the risk of distant recurrence in patients with intermediate or high-risk early-stage breast cancer. The duration of therapy varies, and eligibility criteria overlap; however, the recent NATALEE trial included a diverse population, including an intermediate-risk group (stage II, node-negative with additional risk factors) to evaluate the role of the CDK4/6 inhibitors among such populations. The striking aspect of this trial was the carry-over effect, shown most clearly in the monarchE study with 5-year follow-up. Even 3 years after completing treatment with abemaciclib, the data showed an increasing impact on disease-free survival and distant disease-free survival. Although there has been no overall survival impact yet, fewer patients with abemaciclib in monarchE are living with metastatic disease. What are the most critical research gaps or upcoming trials that could reshape how we manage HR+ early-stage breast cancer in the upcoming years? A few main things to address are improving risk stratification, how to use ctDNA to improve outcome, and understanding if use of oral selective estrogen receptor degrader (SERDs) in sequence improve outcome and their optimal therapy duration. So far, studies using ctDNA to assess risk and guide therapy changes have been challenging due to the low number of positive ctDNA results. Moreover, ctDNA detection has sometimes coincided with metastatic disease already visible on scans in case of several aggressive cancers. We still don't know the optimal treatment approach when molecular evidence of disease is found, which is making studies focus on adding targeted therapy or changing endocrine therapy. Several trials are evaluating oral SERDs in the early stage setting for the treatment of high-risk disease. While these trials will also collect ctDNA, patient eligibility is not based on these tests. One very important area that requires additional research is understanding early-stage breast cancer in young women, where tumors seem to behave poorly — particularly in women under the age of 40 — even when patients are treated with optimal therapy. Understanding optimal therapy is a key research focus, and further investigation of biological drivers in both ductal and lobular cancers is warranted. The OFFSET trial aims to determine the value of adjuvant chemotherapy vs ovarian function suppression in conjunction with standard endocrine therapy and CDK4/6 inhibitors as indicated. However, this study is challenging to enroll in. Hope S. Rugo, MD, FASCO, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Chugai; Puma; Sanofi; Napo; Mylan Received research grant from: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics; OBI Pharma; Ambrx

Lightware Revolution: Powering Business With Quantum Coherence
Lightware Revolution: Powering Business With Quantum Coherence

Forbes

time8 minutes ago

  • Forbes

Lightware Revolution: Powering Business With Quantum Coherence

Dr. Pravir Malik is the founder and technologist of QIQuantum and the Forbes Technology Council group leader for Quantum Computing. When Tony Hsieh and the Zappos leadership team asked me to scale up the 'Cosmology of Light' workshops—chronicled in a two-part Forbes series—at the end of 2019 to also target external audiences, the invitation felt audacious even by the company's boundary-shattering standards. In those months, hundreds of employees—and, once the pandemic hit, thousands of online participants—closed their eyes, envisioned a radiant sphere of light at their core and invited their most stubborn personal or professional challenges into that luminous space. What's striking is how the core shift facilitated in the workshop mirrors the process of quantum computation. Light-Algorithms And Quantum Computation Let's first look at quantum computation in more detail. It begins by placing qubits into states of superposition and entanglement, allowing simultaneous exploration of many computational pathways. These qubits then evolve coherently, guided by a carefully sequenced set of quantum gates—the components of the algorithm. As the system progresses, these pathways interfere: Incorrect paths cancel out, while correct ones are amplified. The algorithm's effectiveness depends on maintaining coherence throughout this evolution, so that constructive interference can clearly reveal the most probable—or optimal—outcome at the moment of measurement. Now, let's look at the parallels at the human level. In the workshop setting, a participant begins by envisioning a globe of light radiating from their center—an act that invites a surrender to the 'logic' of that light. As the mind and heart settle, inner dialogue quiets and judgment recedes, a field of expanded awareness emerges. This is the human equivalent of superposition: multiple possibilities becoming simultaneously perceptible. The challenge to be addressed is then consciously introduced into this luminous space, entangling with it. Verbal cues and subtle instructions from the facilitator act as quantum gates, shaping the evolution of the algorithm. A successful light-algorithm culminates in a distinct somatic shift—a felt bodily signal that the process has completed. To test its efficacy, participants are encouraged to apply the method to one of two similar real-life situations, leaving the other untouched, and observe which yields the more constructive outcome in the following weeks. Quantum Computation Across Scale In earlier Forbes writings—beginning with "Learning From An Atom-Based Quantum Computer"—I've proposed that if the atom functions as nature's foundational quantum computer, then so must molecules, and by logical extension, all complex structures: cells, organisms, ecosystems—even people. Why then wouldn't the light-algorithm at the heart of these workshops also be a legitimate quantum computational process? We often assume that the quantum and classical worlds are fundamentally disconnected. The quantum is 'weird'—governed by uncertainty, nonlocality and entanglement—while the macro-world is logical and ordered. But perhaps this split reflects more of a perceptual bias than a truth. What if the unpredictability, strange synchronicities and nonlinear leaps we witness in human life and organizations are not separate from quantum behavior but extensions of it—the same weirdness expressed at a different scale? If so, then many so-called quantum oddities may not be odd at all. They may simply be universal patterns we've failed to recognize as continuous across the micro and macro. This reframes both life and physics: The quantum becomes familiar, and the familiar reveals its quantum depths. The Emergence Of Lightware Recognizing people, teams and organizations as nature-based quantum computers—systems that, like their engineered counterparts, require coherence-enhancing tools—introduces a new imperative for technological design. Imagine enterprise platforms that detect cognitive overload and dynamically reconfigure workflows to restore team-wide quantum coherence. Envision wearable devices that convert biometric patterns into a real-time "quantum-coherence index," gently nudging users toward stillness, where insight becomes most probable. Take it further to participatory AIs, trained on thousands of light-algorithm transcripts, which design personalized quantum interventions for healing, insight and innovation. Such AI involvement may reveal that 'soft skills' such as mindfulness, empathy and psychological safety are, in fact, analogous to error correction, noise mitigation and decoherence controls, respectively. At the furthest edge of this vision lies a future where entire organizations operate not as hierarchies or even networks but as coherent light fields, where strategic intent propagates through resonance rather than reporting lines. Taken together, these scenarios describe an emerging category that can be called 'lightware'—technologies engineered not just to process information but to entrain quantum coherence across biological, social and digital strata. A Quantum Opportunity The timing for such a leap is fortuitous. Photonic and neutral-atom quantum processors are rapidly advancing toward error-corrected performance. As I explored in a previous Forbes article, a QIQD (quaternary interpretation of quantum dynamics) perspective suggests that when light interacts with atoms, it doesn't merely shift energy—it extracts meaning. This opens a profound technological opportunity: to leverage QIQD-informed photonic-atomic processors in the development of lightware. Meaning-based processing could provide the foundation for a new ontology—one capable of translating the petabytes of behavioral data generated by wearables and agentic large language models into actionable metrics of quantum coherence. As hybrid work proliferates and AI-driven automation accelerates, this approach offers a timely and necessary response to the rising demand for deeper, more resonant forms of engagement. Quantum coherence may offer a measurable, trainable indicator that transcends productivity dashboards and employee-sentiment polls. Venture funds are already scouting startups that translate quantum principles into leadership development, culture engineering and decision support. Expect seed rounds for coherence-analytics platforms within the next couple of years and Series A investments in hardware-software quantum-coherence bundles soon thereafter. Much as pocket calculators demystified arithmetic, lightware may render quantum 'weirdness' a daily business tool and urge executives to stop questioning whether quantum thinking applies to enterprise life and start asking how quickly they can deploy it. The question facing leaders now is simple: Will you wait for quantum coherence to emerge by accident, or will you design for it on purpose? Those who choose the latter may discover that technological leaps aren't just about speed, precision or control but about quantum coherence. And that the next great innovation won't just be built on silicon or code—but on light. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

'War of the Worlds' Isn't Just Bad. It's Also Shameless Tech Propaganda
'War of the Worlds' Isn't Just Bad. It's Also Shameless Tech Propaganda

WIRED

time38 minutes ago

  • WIRED

'War of the Worlds' Isn't Just Bad. It's Also Shameless Tech Propaganda

Aug 13, 2025 10:00 AM By making Big Tech the hero in a movie about government surveillance, the dismally rated remake feels more like an ad for Amazon than anything else. Still from War of the Worlds. Courtesy of Universal/Courtesy Everett Collection 'Here we go' is both the first line of the 2025 Amazon Prime movie War of the Worlds and exactly what I said when I chose to watch it after the shitstorm of reviews that warned me not to. Directed by Rich Lee and shot exclusively through online calls and surveillance feed POVs, War of the Worlds centers around domestic terror analyst William Radford, played by Ice Cube, who is on a mission to save his family and the country from alien cyborgs who are deadset on eating our data. Literally. At first glance, the film's three percent rating on Rotten Tomatoes—up from zero percent when it debuted—seems both impressive and predictable. While getting a rating below five percent seems like a difficult feat, remaking a classic (1953's The War of the Worlds has 89 percent on Rotten Tomatoes), is going to set some pretty high standards. Top that with setting an action film through the lens of Microsoft Teams meetings and poor CGI, and you're bound to make even the most tolerant viewer roll their eyes. But graphics and clearance issues aside (I mean seriously, what was with all of the blurred out faces?), the tech-based plotholes that bordered on propaganda took away from the film's message on the importance of human connection. The most jarring examples are the inconsistencies of technological availability after the data-hungry aliens take out Earth's satellites. Military weapons, vehicle GPS systems, and Facebook page outages wreak physical and emotional havoc across the world, but somehow news networks, Starlink satellites, X feeds, and Amazon purchase access remain unscathed just a few scenes later with little-to-no explanation. Radford's office is locked when he tries to leave to save his daughter, but is somehow open when he has to hack the data servers in the basement— after the building is put on an additional, air-sealed lockdown. Most ridiculously, a Prime Air drone is able to dodge through apocalyptic levels of destruction and mayhem to deliver a worldsaving thumbdrive to the DHS building. The shameless promotion of tech brands doesn't end there. Radford's daughter, Faith, a Georgetown-educated biochemist, somehow has the bright idea of removing a large chunk of debris from her leg—causing near-fatal bleeding. Thankfully, Mark Goodman, her Amazon delivery driver boyfriend, is able to make a tourniquet out of packaging tape because, according to him, he's a 'pro.' Even minor characters get caught up in the 'Amazon Savior' motif. When the worldsaving Amazon Prime Air drone overturns on the way to the DHS building, a houseless person only helps to fix it after being rewarded with a $1,000 Amazon gift card. These scenes in War of the Worlds would have been just outrageous enough to be chalked up to comedy, if it wasn't for the film's heightened focus on government surveillance without any mention of the tech industry's role in all this. From Anonymous-style livestreams featuring the US constitution, to Radford digitally stalking his children, and the secret data-stealing project that beacons the aliens to Earth, the true enemy is clear: the US government and its technology. In fact, the only time privacy is threatened as it relates to private businesses is when the government interferes with it. For example, Radford uses Guardian, the government's surveillance software system, to hack into a Tesla, and remotely take his hurt daughter to a safer location. In the beginning of the film, David, Radford's son, insults his father by saying his career consists of nothing more than spying on people's Amazon shopping carts. Most importantly, the secret government program Goliath, which is the ultimate reason why the alien cyborgs invaded, cyphons billions of dollars worth of private data conversations from the American people. There is zero mention of tech juggernauts like Jeff Bezos or Elon Musk being linked to controversial data collection processes, from failing to protect personal data to staging a full blown digital coup in the US government. Hardly surprising, considering it's an Amazon movie, but it still feels like a glaring omission. If I had to say something nice about War of the Worlds , Lee took a risk remaking a beloved thriller through an internet-first POV. While risks can pay off—this didn't. The decision to demonize government surveillance while making Big Tech the passive victims ultimately water down the film's message—making it more of a near-90 minute commercial for brands like Amazon and Microsoft than food for thought. But hey, maybe all this promo means Amazon Air will finally be available in Washington, DC, at least.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store